Drug intelligence / Profile preview

IKS01

Development stage: Preclinical
Lead developer: Iksuda Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IKS01 is an investigational **folate receptor alpha-targeted antibody-drug conjugate** developed by Iksuda Therapeutics for solid tumors, particularly ovarian cancer and non-small-cell lung cancer. The molecule comprises the FRA-binding antibody Isumab01 linked through Iksuda's PermaLink conjugation technology to Femtogenix's FGX2-62 payload, a next-generation pyridinobenzodiazepine DNA mono-alkylator. In preclinical studies, IKS01 showed anti-tumor activity and tumor regression in ovarian and lung cancer models, including platinum-resistant settings, and was designed to retain activity in tumors with low to moderate folate receptor alpha expression.

Targets

FOLR1 (FRα)DNA

Beyond the preview

Go deeper on IKS01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IKS01.

Explore the full profile